Results 1 to 10 of about 230,357 (266)

Liver-Targeting of Interferon-Alpha with Tissue-Specific Domain Antibodies [PDF]

, 2013
PMCID: PMC3581439This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trahtenherts, A Walker, Adam Walker, AM Wu, Armin Sepp, B Saunier, C. Andrew Boswell, CL Van Broekhoven, Clare Mudd, DJ Peng, DY Yang, E Dieperink, Edward Coulstock, ES Ward, F Pacifico, G Dusheiko, Gráinne Dunlevy, Jane Sosabowski, Jerome Burnet, JH Park, Julie Foster, KA Deal, Laura Goodall, LC Platanias, LJ Holt, LJ Holt, M Abe, M Loignon, M Spiess, Marie Davies, Milan Ovečka, MW Fried, MW Fried, P Kallinteri, R Duncan, R Gay, R Iorio, Rob Prince, T Eto, U Iyer, U Treichel, WM Pardridge, XQ Zhang, Y Zhang, YI Jeong, YY Seow   +45 more
core   +13 more sources

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Berg, Thomas, Hoffmann, Robert M., Hopf, Uwe, Lafrenz, Michael, Leifeld, Ludger, Pape, Gerd R., Spengler, Ulrich, Teuber, Gerlinde, Zeuzem, Stefan   +8 more
core   +1 more source

Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. [PDF]

, 2003
Roughly 50% of patients with chronic hepatitis C, who relapsed after a previous monotherapy with interferon alpha, will respond in a sustained fashion to 24 weeks of re-therapy with the combination of interferon alpha plus ribavirin.
August-Jörg, B.S., Borovicka, J., Dufour, J.F., Gonvers, J.J., Henz, S., Hermann, R., Meyenberger, C., Renner, E.L., Weitz, M.   +8 more
core   +1 more source

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Porcine innate and adaptative immune responses to influenza and coronavirus infections [PDF]

, 2006
Both innate and adaptative immune responses contribute to the control of infectious diseases, including by limiting the spreading of zoonotic diseases from animal reservoirs to humans.
Asselin-Paturel, Baudoux, BERNARD CHARLEY, Brim, Charley, Charley, Charley, Chen, Chinsangaram, Corthier, Fitzgerald-Bocarsly, Guzylack-Piriou, Heinen, KRISTIEN VAN REETH, La Bonnardière, Laude, Laude, Le Bon, Lim, Liu, Palese, Peiris, Pestka, Riffault, Riffault, Riffault, Rothenfusser, SABINE RIFFAULT, Saif, Siegal, Summerfield, Tu, Tudor, Van Reeth, Van Reeth, van Reeth   +35 more
core   +2 more sources

Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]

, 2000
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B., Grunze, Heinz, Loeschke, K., Schlösser, S., Schmidt, F., Schäfer, Martin   +5 more
core   +1 more source

Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. [PDF]

, 2012
We describe the course and likely pathophysiology of impending anterior ischemic optic neuropathy (AION) and retinal vein occlusion in a 56-year-old man with polycythemia vera managed with interferon alpha for 2 years.
Hirsch, Louis K, Rue, Kelly S, Sadun, Alfredo A   +2 more
core   +1 more source

The treatment of hepatitis C: history, presence and future [PDF]

, 2004
The treatment of chronic hepatitis C has made remarkable progress over the past two decades. For interferon-alpha monotherapy, sustained virological response rates were between 2 and 9% in genotype 1 and between 16 and 23% in genotypes ...
Knegt, R.J. (Robert) de, Orlent, H. (Hans), Schalm, S.W. (Solko), Veldt, B.J. (Bart), Vrolijk, J.M. (Jan)   +4 more
core   +6 more sources

Complete replication of hepatitis C virus in cell culture. [PDF]

, 2005
Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen.
Burton, Dennis R, Evans, Matthew J, Hynes, Richard O, Lindenbach, Brett D, Liu, Christopher C, Maruyama, Toshiaki, McKeating, Jane A, Rice, Charles M, Syder, Andrew J, Tellinghuisen, Timothy L, Wölk, Benno   +10 more
core   +1 more source

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source